Corrigendum to “Combined sulforaphane and β-sitosterol mitigate against olanzapine-induced metabolic disorders in rats: Insights on FOXO, PI3K/AKT, JAK/STAT3, and MAPK signaling pathways” [Int. Immunopharmacol. 140 (2024) 112904]
Titel:
Corrigendum to “Combined sulforaphane and β-sitosterol mitigate against olanzapine-induced metabolic disorders in rats: Insights on FOXO, PI3K/AKT, JAK/STAT3, and MAPK signaling pathways” [Int. Immunopharmacol. 140 (2024) 112904]
Auteur:
El-Shoura, Ehab A.M. Abdelzaher, Lobna A. Mahmoud, Nesreen I. Farghaly, Omar A. Sabry, Mostafa Shahataa, Mary Girgis Salem, Esraa A. Saad, Hebatallah M. Elhussieny, Omnya Kozman, Magy R. Atwa, Ahmed M.